Lisa V. Kalman

Centers for Disease Control and Prevention — UG

Biochemistry, Genetics and Molecular Biology · Life Sciences

33h-index3.6kcitations69works18.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Genomics and Rare Diseases(18), Pharmacogenetics and Drug Metabolism(16), Cancer Genomics and Diagnostics(10), Pharmaceutical studies and practices(8), Bacterial Genetics and Biotechnology(7)

Publications69 total

From Expert Knowledge to Validation Resources
Journal of Molecular Diagnostics·2025Open Access
Gaps in guideline adherence: evaluating HLA-B*57:01 screening for abacavir sensitivity and the implementation of evidence-based HIV care
Clinical Biochemistry·2025Open Access
New Resources to Identify Characterized DNA Reference Materials for Pharmacogenetic (PGx) and Human Leukocyte Antigen (HLA) Testing
Journal of Molecular Diagnostics·2025· 2 citedOpen Access
Characterization of Reference Materials for DPYD
Journal of Molecular Diagnostics·2024· 2 citedOpen Access
DPYD Genotyping Recommendations
Journal of Molecular Diagnostics·2024· 42 citedOpen Access
2023 Australian guideline for assessing and managing cardiovascular disease risk
The Medical Journal of Australia·2024· 66 citedOpen Access
CYP3A4 and CYP3A5 Genotyping Recommendations
Journal of Molecular Diagnostics·2023· 61 citedOpen Access
Characterization of Reference Materials for CYP3A4 and CYP3A5
Journal of Molecular Diagnostics·2023· 13 citedOpen Access
New Australian guideline and calculator for assessing and managing cardiovascular disease risk
Heart Lung and Circulation·2023· 1 citedOpen Access
Table of Contents
Journal of Molecular Diagnostics·2022Open Access
Characterization of Reference Materials for TPMT and NUDT15
Journal of Molecular Diagnostics·2022· 18 citedOpen Access
TPMT and NUDT15 Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase
Journal of Molecular Diagnostics·2022· 70 citedOpen Access
Trends in guideline implementation: an updated scoping review
Implementation Science·2022· 144 citedOpen Access
CYP2C8, CYP2C9, and CYP2C19 Characterization Using Next-Generation Sequencing and Haplotype Analysis
Journal of Molecular Diagnostics·2022· 44 citedOpen Access
Creation of an Expert Curated Variant List for Clinical Genomic Test Development and Validation
Journal of Molecular Diagnostics·2021· 7 citedOpen Access
Creation of an Expert Curated Variant List for Clinical Genomic Test Development and Validation: A ClinGen and GeT-RM Collaborative Project
2021· 1 citedOpen Access
Recommendations for Clinical CYP2D6 Genotyping Allele Selection
Journal of Molecular Diagnostics·2021· 142 citedOpen Access
Characterization of Reference Materials with an Association for Molecular Pathology Pharmacogenetics Working Group Tier 2 Status: CYP2C9, CYP2C19, VKORC1, CYP2C Cluster Variant, and GGCX
Journal of Molecular Diagnostics·2021· 15 citedOpen Access
Characterization of Reference Materials for Spinal Muscular Atrophy Genetic Testing
Journal of Molecular Diagnostics·2020· 9 citedOpen Access
Characterization of 107 Genomic DNA Reference Materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: A GeT-RM and Association for Molecular Pathology Collaborative Project
UNC Libraries·2020· 10 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Victoria M. Pratt(21), Stuart A. Scott(11), Karen E. Weck(10), Lorraine H. Toji(10), Andrea Gaedigk(9), Ann M. Moyer(8), Barbara A. Zehnbauer(7), Ira M. Lubin(7), Houda Hachad(7), Amy Turner(7), Kasinathan Muralidharan(7), Elaine Lyon(6), Ulrich Broeckel(6), Reynold C. Ly(6), Arlene Buller(6), Daniel H. Farkas(5), Yuan Ji(5), Larisa H. Cavallari(5), Ron H. N. van Schaik(5), Michelle Whirl‐Carrillo(5)